abstract: UNASSIGNED: 1545 Background. @entity5 ( @entity3271 ) is associated with @entity7499 ( @entity1373 , vascular proliferation of leaking vessels and @entity5 @entity39 ). Our aim was to evaluate the prognostic value of @entity5 angiogenesis assessed by pathological and radiological examinations on progression-free (PFS) and @entity1349 ( @entity1349 ) in @entity1 (pts) with @entity3271 . METHODS: All pts with @entity3271 consecutively treated in our Institution from 1994-2000. Pathological sections were re-evaluated to confirm the diagnosis of ODs and to assess the degree of nuclear atypia, @entity4498 , @entity1373 , and @entity39 . CT-scan and/or MRI images were re-analyzed to assess contrast enhancement and @entity39 . A multivariate analysis was performed including baseline demographic data, histological and radiological factors associated with @entity5 angiogenesis and treatment. RESULTS: 134 pts with histologically confirmed low grade (WHO grade II, n=49) and anaplastic @entity3271 (WHO grade III, n=85) were analyzed. Univariate analysis showed that prognostic factors associated with better PFS and @entity1349 were age <55 (p<0.0001), @entity3271 revealed by @entity410 (p<0.0001), lack of @entity1373 (p<0.001), lack of contrast enhancement (p=0.02), and lack of histological/radiological evidence of @entity5 @entity39 (p<0.0001). Multivariate analysis identified @entity39 , @entity1373 and/or contrast enhancement, age, and @entity410 as independent bad-prognostic factors for @entity1349 . This enabled us to defined three pts groups (low, intermediate, and high risk @entity3271 ) according to NEVA score using the more robust parameters ( @entity39 , @entity302 , vessel and age). CONCLUSION: Endothelial hyperplasia, contrast enhancement, and @entity39 that reflect a mutli-step development of @entity5 angiogenesis are independent factors of bad prognosis in pts with @entity3271 . No significant financial relationships to disclose.

title: Baseline pathological and radiological assessment of XXXX angiogenesis predicts survival in @entity1 with @entity3271 .

answer: @entity5 :: (MESH:D009369,Disease) :: ['tumor']


abstract: UNASSIGNED: 1545 Background. @entity5 ( @entity3271 ) is associated with @entity7499 ( @entity1373 , vascular proliferation of leaking vessels and @entity5 @entity39 ). Our aim was to evaluate the prognostic value of @entity5 angiogenesis assessed by pathological and radiological examinations on progression-free (PFS) and @entity1349 ( @entity1349 ) in @entity1 (pts) with @entity3271 . METHODS: All pts with @entity3271 consecutively treated in our Institution from 1994-2000. Pathological sections were re-evaluated to confirm the diagnosis of ODs and to assess the degree of nuclear atypia, @entity4498 , @entity1373 , and @entity39 . CT-scan and/or MRI images were re-analyzed to assess contrast enhancement and @entity39 . A multivariate analysis was performed including baseline demographic data, histological and radiological factors associated with @entity5 angiogenesis and treatment. RESULTS: 134 pts with histologically confirmed low grade (WHO grade II, n=49) and anaplastic @entity3271 (WHO grade III, n=85) were analyzed. Univariate analysis showed that prognostic factors associated with better PFS and @entity1349 were age <55 (p<0.0001), @entity3271 revealed by @entity410 (p<0.0001), lack of @entity1373 (p<0.001), lack of contrast enhancement (p=0.02), and lack of histological/radiological evidence of @entity5 @entity39 (p<0.0001). Multivariate analysis identified @entity39 , @entity1373 and/or contrast enhancement, age, and @entity410 as independent bad-prognostic factors for @entity1349 . This enabled us to defined three pts groups (low, intermediate, and high risk @entity3271 ) according to NEVA score using the more robust parameters ( @entity39 , @entity302 , vessel and age). CONCLUSION: Endothelial hyperplasia, contrast enhancement, and @entity39 that reflect a mutli-step development of @entity5 angiogenesis are independent factors of bad prognosis in pts with @entity3271 . No significant financial relationships to disclose.

title: Baseline pathological and radiological assessment of @entity5 angiogenesis predicts survival in XXXX with @entity3271 .

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'seizures']

entities_list: @entity7499 :: ('MESH:D016510', 'Disease') :: ['increased angiogenesis']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Malignant transformation of oligodendrogliomas']

entities_list: @entity1373 :: ('MESH:D006965', 'Disease') :: ['endothelial hyperplasia']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: UNASSIGNED: 5005 Background: Most @entity1 (pts) with @entity43 relapse. ICON 4 - AGO OVAR 2.2 results suggest combination C-based therapy may be superior to single agent C. GC is a feasible less neurotoxic regimen and thus of interest to evaluate in this setting. METHODS: In this phase III trial pts with @entity902 sensitive recurrent @entity43 (>=  6 months after the end of primary therapy) were randomized to receive C (AUC 4 d1) plus G (1000 mg/m(2) @entity17079 ) or C (AUC 5 d1) every 3 weeks. The primary objective compared progression free survival (PFS) in both arms. Secondary objectives were response rate (RR) and duration, overall survival (OS), @entity137 and quality of life (QoL). RESULTS: From 09/99 and 04/02, 356 pts (178 GC, 178 C) were randomized. Both study arms were well balanced for baseline disease characteristics. Median number of cycles was 6 for GC (0-10) and C (0-9). The weekly dose intensity was 98.2% for C (C arm) and 96.2% for C and 75.6% (92.8% for @entity12840 and 63.4% for d8) for G (GC arm). Grade 3/4 hematologic @entity137 were significant higher in the GC arm ( @entity417 27.4% of pts. vs. 8.0%, @entity1398 70.3% vs. 12.0%, @entity882 34.9% vs. 11.4%). @entity1261 or @entity2841 was more often used in GC (23.6% of pts. vs. 10.1%) as well as red cell transfusions (37.1% vs. 14.6%). Clinical sequelae were similar between arms: @entity1398 (1.1% GC vs. 0% C) and infections (0.6% for both arms). Grade 3/4 non-hematologic @entity137 were infrequent in both arms (< 5%), especially for @entity16 (1.1% GC vs. 1.7% C). Overall RR for GC was 47.2% (95% CI: 39.9-54.5%) and 30.9% (95% CI: 24.1-37.7) for C (p= 0.0016). GC pts reported significantly faster palliation of abdominal symptoms as well as significantly improved global QoL. With a median follow up of 13 months, median PFS was 8.6 mo (95%CI: 8.0-9.7) for GC and 5.8 mo (95% CI: 5.2-7.1) for C (HR 0.72 [95% CI: 0.57-0.90], p= 0.0038, e= 311). OS data are immature and this study was not powered to detect differences in OS. CONCLUSION: The combination of G plus C improves PFS and QoL in @entity902 sensitive recurrent @entity43 @entity1 with acceptable @entity137 . [Table: see text].

title: Gemcitabine/carboplatin (GC) vs. carboplatin (C) in @entity902 sensitive recurrent @entity43 ( XXXX ). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['sensory neuropathy']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'febrile neutropenia']

entities_list: @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']

answer: @entity43 :: (MESH:D010051,Disease) :: ['OVCA']


abstract: UNASSIGNED: 5005 Background: Most @entity1 (pts) with @entity43 relapse. ICON 4 - AGO OVAR 2.2 results suggest combination C-based therapy may be superior to single agent C. GC is a feasible less neurotoxic regimen and thus of interest to evaluate in this setting. METHODS: In this phase III trial pts with @entity902 sensitive recurrent @entity43 (>=  6 months after the end of primary therapy) were randomized to receive C (AUC 4 d1) plus G (1000 mg/m(2) @entity17079 ) or C (AUC 5 d1) every 3 weeks. The primary objective compared progression free survival (PFS) in both arms. Secondary objectives were response rate (RR) and duration, overall survival (OS), @entity137 and quality of life (QoL). RESULTS: From 09/99 and 04/02, 356 pts (178 GC, 178 C) were randomized. Both study arms were well balanced for baseline disease characteristics. Median number of cycles was 6 for GC (0-10) and C (0-9). The weekly dose intensity was 98.2% for C (C arm) and 96.2% for C and 75.6% (92.8% for @entity12840 and 63.4% for d8) for G (GC arm). Grade 3/4 hematologic @entity137 were significant higher in the GC arm ( @entity417 27.4% of pts. vs. 8.0%, @entity1398 70.3% vs. 12.0%, @entity882 34.9% vs. 11.4%). @entity1261 or @entity2841 was more often used in GC (23.6% of pts. vs. 10.1%) as well as red cell transfusions (37.1% vs. 14.6%). Clinical sequelae were similar between arms: @entity1398 (1.1% GC vs. 0% C) and infections (0.6% for both arms). Grade 3/4 non-hematologic @entity137 were infrequent in both arms (< 5%), especially for @entity16 (1.1% GC vs. 1.7% C). Overall RR for GC was 47.2% (95% CI: 39.9-54.5%) and 30.9% (95% CI: 24.1-37.7) for C (p= 0.0016). GC pts reported significantly faster palliation of abdominal symptoms as well as significantly improved global QoL. With a median follow up of 13 months, median PFS was 8.6 mo (95%CI: 8.0-9.7) for GC and 5.8 mo (95% CI: 5.2-7.1) for C (HR 0.72 [95% CI: 0.57-0.90], p= 0.0038, e= 311). OS data are immature and this study was not powered to detect differences in OS. CONCLUSION: The combination of G plus C improves PFS and QoL in @entity902 sensitive recurrent @entity43 @entity1 with acceptable @entity137 . [Table: see text].

title: Gemcitabine/carboplatin (GC) vs. carboplatin (C) in @entity902 sensitive recurrent XXXX ( @entity43 ). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG.

answer: @entity43 :: (MESH:D010051,Disease) :: ['ovarian cancer']


abstract: UNASSIGNED: 5005 Background: Most @entity1 (pts) with @entity43 relapse. ICON 4 - AGO OVAR 2.2 results suggest combination C-based therapy may be superior to single agent C. GC is a feasible less neurotoxic regimen and thus of interest to evaluate in this setting. METHODS: In this phase III trial pts with @entity902 sensitive recurrent @entity43 (>=  6 months after the end of primary therapy) were randomized to receive C (AUC 4 d1) plus G (1000 mg/m(2) @entity17079 ) or C (AUC 5 d1) every 3 weeks. The primary objective compared progression free survival (PFS) in both arms. Secondary objectives were response rate (RR) and duration, overall survival (OS), @entity137 and quality of life (QoL). RESULTS: From 09/99 and 04/02, 356 pts (178 GC, 178 C) were randomized. Both study arms were well balanced for baseline disease characteristics. Median number of cycles was 6 for GC (0-10) and C (0-9). The weekly dose intensity was 98.2% for C (C arm) and 96.2% for C and 75.6% (92.8% for @entity12840 and 63.4% for d8) for G (GC arm). Grade 3/4 hematologic @entity137 were significant higher in the GC arm ( @entity417 27.4% of pts. vs. 8.0%, @entity1398 70.3% vs. 12.0%, @entity882 34.9% vs. 11.4%). @entity1261 or @entity2841 was more often used in GC (23.6% of pts. vs. 10.1%) as well as red cell transfusions (37.1% vs. 14.6%). Clinical sequelae were similar between arms: @entity1398 (1.1% GC vs. 0% C) and infections (0.6% for both arms). Grade 3/4 non-hematologic @entity137 were infrequent in both arms (< 5%), especially for @entity16 (1.1% GC vs. 1.7% C). Overall RR for GC was 47.2% (95% CI: 39.9-54.5%) and 30.9% (95% CI: 24.1-37.7) for C (p= 0.0016). GC pts reported significantly faster palliation of abdominal symptoms as well as significantly improved global QoL. With a median follow up of 13 months, median PFS was 8.6 mo (95%CI: 8.0-9.7) for GC and 5.8 mo (95% CI: 5.2-7.1) for C (HR 0.72 [95% CI: 0.57-0.90], p= 0.0038, e= 311). OS data are immature and this study was not powered to detect differences in OS. CONCLUSION: The combination of G plus C improves PFS and QoL in @entity902 sensitive recurrent @entity43 @entity1 with acceptable @entity137 . [Table: see text].

title: Gemcitabine/carboplatin (GC) vs. carboplatin (C) in XXXX sensitive recurrent @entity43 ( @entity43 ). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG.

answer: @entity902 :: (MESH:D010984,Chemical) :: ['platinum']


abstract: UNASSIGNED: 5059 Background: Only a subset of @entity1 responds to a given chemotherapeutic regimen. The purpose of this analysis was to determine whether @entity5 are generally sensitive or resistant regardless of regimen, or do they demonstrate heterogeneity in responsiveness across regimens. METHODS: We examined the ex vivo chemoresponse of @entity43 cells from 256 @entity1 across 9 practices. An average of 8 drug regimens, including combinations, were tested per @entity5 . The assay results were scored for sensitivity or resistance based on live cell number after exposure to varied concentrations of each chemotherapeutic regimen. @entity1 were classified into three groups: predominantly sensitive (>83% of regimens tested scored sensitive for their @entity5 ), predominantly resistant (>83% tested resistant), and heterogeneous. RESULTS: 51 of 256 (20%) cases were predominantly sensitive, with a median progression free interval (PFI) of 17.7 months. 34 (13%) cases were predominantly resistant, with a median PFI of 9.9 months. Two thirds of cases (N=171) exhibited heterogeneity of response, with a median PFI of 11.4 months. Within the heterogeneous group, those who received a regimen scored as sensitive ex-vivo (no other regimens tested were scored more sensitive than the regimen they received) vs resistant ex-vivo had an improved median PFI: 12.4 months (N=46) vs 8.6 months (N=125). CONCLUSIONS: The majority of @entity5 tested demonstrated heterogeneity of response ex vivo. As heterogeneity of chemotherapy response for an individual @entity1 cannot be assessed clinically, an ex vivo assay assessment is informative. Moreover, our data suggests that individualizing therapy by incorporating an ex vivo assay has the potential to increase the response rates to chemotherapy. [Table: see text].

title: Heterogeneity in XXXX as demonstrated by an ex vivo chemo response assay.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'patient']

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

answer: @entity43 :: (MESH:D010051,Disease) :: ['chemoresponsiveness of ovarian cancer']


abstract: BACKGROUND: The long-term success of lung transplantation is challenged by the development of @entity358 ( @entity358 ) and its distinct subtypes of @entity4154 ( @entity4154 ) and restrictive allograft syndrome (RAS). However, the current diagnostic criteria for @entity358 subtypes rely on total lung capacity (TLC), which is not always measured during routine post-transplant assessment. Our aim was to investigate the utility of low-dose 3-dimensional computed tomography (CT) lung volumetry for differentiating RAS from @entity4154 . METHODS: This study was a retrospective evaluation of 63 @entity1 who had developed @entity358 after bilateral lung or heart   lung transplantation between 2006 and 2011, including 44 @entity4154 and 19 RAS cases. Median post-transplant follow-up was 65 months in @entity4154 and 27 months in RAS. The median interval between baseline and the disease-onset time-point for CT volumetry was 11 months in both @entity4154 and RAS. Chronologic changes and diagnostic accuracy of CT lung volume (measured as percent of baseline) were investigated. RESULTS: RAS showed a significant decrease in CT lung volume at disease onset compared with baseline (mean 3,916 ml vs 3,055 ml when excluding opacities, p < 0.0001), whereas @entity4154 showed no significant post-transplant change (mean 4,318 ml vs 4,396 ml, p = 0.214). The area under the receiver operating characteristic curve of CT lung volume for differentiating RAS from @entity4154 was 0.959 (95% confidence interval 0.912 to 1.01, p < 0.0001) and the calculated accuracy was 0.938 at a threshold of 85%. CONCLUSION: In bilateral lung or heart   lung transplant @entity1 with @entity358 , low-dose CT volumetry is a useful tool to differentiate @entity1 who develop RAS from those who develop @entity4154 .

title: Low-dose computed tomography volumetry for subtyping XXXX .

entities_list: @entity4154 :: ('MESH:D001989', 'Disease') :: ['BOS', 'bronchiolitis obliterans syndrome']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['CLAD', 'chronic lung allograft dysfunction']

answer: @entity358 :: (MESH:D008171,Disease) :: ['chronic lung allograft dysfunction']


abstract: UNASSIGNED: 5113 Background: @entity417 was found to be an adverse prognostic factor and associated with poorer response to treatment and decreased survival in @entity1 undergoing primary radiotherapy or radiochemotherapy for advanced @entity189 of the uterine cervix. This study was to determine the influence of @entity417 in the postoperative adjuvant treatment situation. METHODS: By chart review a collective of 183 @entity1 who received adjuvant radiotherapy because of risk factors after radical surgery (n=109) or inadequate surgery (simple hysterectomy; n=74) were selected. Hemoglobin levels, measured prior to and during adjuvant radiotherapy were analyzed in relation to local control, disease-free and overall survival using Kaplan-Meier analyses and Cox regression analyses. RESULTS: Hemoglobin levels prior to radiotherapy proved to have significant influence on overall (OS) and recurrence-free survival in the entire collective (OS - Log Rank all @entity1 = 7.5; df = 1; p = 0.006). However, analyses of subgroups with risk factors after radical surgery and inadequate surgery show that the observed difference is mainly due to the second group (OS - Log Rank inadequate surgery = 10.8; df = 1; p = 0.001; DFS- Log rankinadequate surgery = 11.6; df = 1; p < 0.001). Multifactorial analyses using Cox regression analyses confirmed the value of hemoglobin levels in comparison with stage and grading. Local control in the named subgroup was also significantly improved. CONCLUSIONS: Normal hemoglobin levels (> 11g/dL) prior to and during adjuvant radiotherapy for @entity189 of the uterine cervix seem to be important especially when @entity1 are treated because of inadvertent simple hysterectomy. No significant financial relationships to disclose.

title: Adjuvant radiotherapy in XXXX of the uterine cervix -The prognostic role of hemoglobin levels.

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinomas']

entities_list: @entity417 :: ('MESH:D000740', 'Disease') :: ['Anemia', 'anemia']

answer: @entity189 :: (MESH:D002277,Disease) :: ['carcinomas']


abstract: UNASSIGNED: 4604 Background: Interferon-alpha ( @entity4020 ) is a standard initial therapy in @entity1358 ( @entity1358 ) with anti- @entity5 effects via immunologic and anti-angiogenic mechanisms. @entity3840 ( @entity3840 ) is an enzyme involved in the formation of @entity1421 and may play a major role in development of @entity5 through numerous mechanisms, including neovascularization. @entity3840 is expressed in the majority of @entity1358 and correlates with stage, grade and microvessel density. Based on potential additive or synergistic anti-antiangiogenic effects, @entity4020 and @entity12698 , an oral @entity3840 inhibitor, were tested in metastatic @entity1358 @entity1 . METHODS: @entity1 with untreated, metastatic @entity1358 received @entity4020 3 MU s.c. daily and @entity12698 400 mg p.o. BID continuously until disease progression or unacceptable @entity137 . Plasma for @entity540 and @entity7 levels was collected at baseline, end of cycles 1, 2, and every other cycle until off-study. Parffin-embedded @entity1358 samples were stained for @entity3840 expression. A 50% increase in the median @entity74 ( @entity74 ) versus historical controls was sought as the primary endpoint. RESULTS: Twenty @entity1 have been treated to date. Two partial responses (10%) have been observed. The median @entity74 is 3.4 months (range 1.2-9.3+ months). There was no increase in observed @entity137 over what was expected from @entity4020 alone. Dose reduction for @entity137 was required to 2 MU QD (6 pts.) and to 1 MU QD (2 pts.). Median @entity74 was longer for pts. who had a treatment-induced decline in @entity540 levels compared with @entity1 with no decline in @entity540 levels (5.6 vs. 3.9 months). The mean % change at cycle 2 versus baseline for @entity540 was inversely correlated with @entity74 (r = -0.5, p = .05). CONCLUSIONS: Combination therapy of low dose, daily @entity4020 and @entity12698 is safe and feasible in metastatic @entity1358 . The final clinical efficacy of this combination is not yet determined. Change in @entity540 levels at cycle 2 versus baseline may predict clinical outcome. Staining of archived @entity1358 samples is ongoing. [Table: see text].

title: A phase II trial of interferon-alpha and XXXX in metastatic renal carcinoma: clinical and anti-angiogenic effects.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity12698 :: ('MESH:C105934', 'Chemical') :: ['celecoxib']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer']

entities_list: @entity1421 :: ('MESH:D015232', 'Chemical') :: ['prostaglandin E2']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell carcinoma', 'RCC tumors', 'RCC', 'RCC tumor']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['TTP', 'time to disease progression']

answer: @entity12698 :: (MESH:C105934,Chemical) :: ['celecoxib']


abstract: UNASSIGNED: 4635 Background: @entity1205 is active for @entity263 ( @entity263 ) and may have additive effects if combined with @entity342 ablation in hormone na  ve disease. Potential beneficial or adverse effects of combination vs sequential chemo-hormonal regimens are poorly defined. The objective of this trial was to assess the tolerability and pathologic effects (including high-throughput transcriptional and immunohistochemical bioprofiling) of 6 months of combined @entity342 ablation + @entity1205 in @entity1 with high risk localized @entity263 prior to radical prostatectomy. METHODS: In a Phase II multicentre, single arm, open-label study @entity1 with newly diagnosed previously untreated clinically localized high-risk disease received @entity342 ablation ( @entity7458 6.3 mg q 8 weeks x 3, + anti- @entity342 for 4 weeks) + weekly @entity1205 (35 mg/m2 iv weekly x 6 q 8 weeks for 3 cycles). RESULTS: 72 @entity1 with a mean age of 55 years (range 45-74) and mean serum PSA of 17.8  g/L (range 2.5-66) were enrolled at 6 sites across Canada. Baseline prognostic factors included 51% cT2 and 38% cT3; 32% Gleason 7, 32% Gleason 8, and 27% Gleason 9; PSA <10 in 44%, 10-20  g/L in 25%, and >20  g/L in 31%. Eight @entity1 discontinued study therapy for > grade 3 @entity137 (n=5), withdrawal of consent (n=1), or identification of metastatic disease (n=2). 64 @entity1 completed protocol therapy and surgery. 38 (59%) were pathological T2N0, including 2 complete responders (P-0) and 10 with residual microfoci of @entity5 . 26 (41%) were pT3, including 7 with seminal vesicle invasion (pT3c), and 4 T3N1. Positive surgical margins were identified in 17 (27%), including 5 pT2 and 12 pT3 @entity5 . CONCLUSION: Combined @entity342 ablation + weekly @entity1205 is reasonably well tolerated and results in significant pathologic responses and lower than expected positive surgical margins for this high-risk group. Tissue microarray construction and transcriptional profiling are underway to define treatment-induced changes in gene expression. [Table: see text].

title: Multicentre phase II trial of combination neoadjuvant hormone therapy and weekly @entity1205 prior to radical prostatectomy in high risk localized XXXX (CUOG-P01a).

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'men']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer', 'HRPC', 'hormone refractory prostate cancer']

entities_list: @entity7458 :: ('MESH:D002064', 'Chemical') :: ['buserelin acetate']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'tumors']

entities_list: @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen']

entities_list: @entity1205 :: ('MESH:C067311', 'Chemical') :: ['Docetaxel', 'docetaxel']

answer: @entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']


abstract: UNASSIGNED: 4635 Background: @entity1205 is active for @entity263 ( @entity263 ) and may have additive effects if combined with @entity342 ablation in hormone na  ve disease. Potential beneficial or adverse effects of combination vs sequential chemo-hormonal regimens are poorly defined. The objective of this trial was to assess the tolerability and pathologic effects (including high-throughput transcriptional and immunohistochemical bioprofiling) of 6 months of combined @entity342 ablation + @entity1205 in @entity1 with high risk localized @entity263 prior to radical prostatectomy. METHODS: In a Phase II multicentre, single arm, open-label study @entity1 with newly diagnosed previously untreated clinically localized high-risk disease received @entity342 ablation ( @entity7458 6.3 mg q 8 weeks x 3, + anti- @entity342 for 4 weeks) + weekly @entity1205 (35 mg/m2 iv weekly x 6 q 8 weeks for 3 cycles). RESULTS: 72 @entity1 with a mean age of 55 years (range 45-74) and mean serum PSA of 17.8  g/L (range 2.5-66) were enrolled at 6 sites across Canada. Baseline prognostic factors included 51% cT2 and 38% cT3; 32% Gleason 7, 32% Gleason 8, and 27% Gleason 9; PSA <10 in 44%, 10-20  g/L in 25%, and >20  g/L in 31%. Eight @entity1 discontinued study therapy for > grade 3 @entity137 (n=5), withdrawal of consent (n=1), or identification of metastatic disease (n=2). 64 @entity1 completed protocol therapy and surgery. 38 (59%) were pathological T2N0, including 2 complete responders (P-0) and 10 with residual microfoci of @entity5 . 26 (41%) were pT3, including 7 with seminal vesicle invasion (pT3c), and 4 T3N1. Positive surgical margins were identified in 17 (27%), including 5 pT2 and 12 pT3 @entity5 . CONCLUSION: Combined @entity342 ablation + weekly @entity1205 is reasonably well tolerated and results in significant pathologic responses and lower than expected positive surgical margins for this high-risk group. Tissue microarray construction and transcriptional profiling are underway to define treatment-induced changes in gene expression. [Table: see text].

title: Multicentre phase II trial of combination neoadjuvant hormone therapy and weekly XXXX prior to radical prostatectomy in high risk localized @entity263 (CUOG-P01a).

answer: @entity1205 :: (MESH:C067311,Chemical) :: ['docetaxel']


abstract: UNASSIGNED: 4633 Background: @entity1311 (T) has shown significant activity both in @entity900 -refractory and untreated @entity2971 @entity1 (pts). In order to determine the impact of T on survival (OS) and @entity137 the analysis compares the results of two prospective trials in pts with 'poor prognosis' @entity2971 . METHODS: In the first trial pts have received high dose @entity3549 chemotherapy ( @entity2033 - @entity3549 ) at dose level [ @entity2879 250 mg/sqm, @entity1260 2 g/sqm, @entity900 20 mg/sqm, d1-5, q d22] for 3 consecutive cycles as part of a phase I/II dose trial. Pts received G-CSF 5  g/kg s.c. from d+1 after treatment to leukocyte recovery >2000/ l and reinfusion of PBSC at day +2. The comparative trial consisted of pts treated in an identical fashion but additionally receiving T at a dose of 225 mg/sqm added on day 1 as a 3-h infusion prior to @entity900 ( @entity2033 - @entity3549 +T. RESULTS: 155 pts have been analyzed, 59 pts in @entity2033 - @entity3549 and 96 pts in @entity2033 - @entity3549 +T. 112 pts and 414 cycles are fully assessable for @entity137 , 152 pts for OS. Pts characteristics ( @entity2033 - @entity3549 compared to HDVIP+T): Median age 29 (16-42) vs. 31 yrs (18-54), mediastinal primary 11 vs. 24%, liver mets 40 vs. 40%, bone 7 vs. 4%, CNS 20 vs. 19%, elevated AFP, @entity6740 , LDH: 39 vs. 30%, 61 vs. 58% and 77 vs. 77%. Dose intensity of the 3- vs. 4-drug regimen achieved have been 98% and 95%. Median time to recovery of granulocytes and thrombocytes (>500/ l resp. >25.000 l) have been day 15 and 16 independent from the addition of T. Differences in grade III/IV @entity137 in favor of @entity2033 - @entity3549 were seen in terms of @entity3136 (14 vs. 49%), @entity221 (3 vs. 20%) and @entity281 (3 vs. 19%) (P.05). 88% of pts attained a favorable response (NED/CR/PRm-) to @entity2033 - @entity3549 compared to 67% in the @entity2033 - @entity3549 +T (P<.05). After a median follow up period of 34 mos (range, 9-78) and 16 (0-47) the calculated 3-yr OS rates were 69.9 (CI95%, 54.3-83.3) for @entity2033 - @entity3549 and 67.3% (56.3-78.3) for @entity2033 - @entity3549 +T (P=.3). Early death rate due to progression/ @entity137 was 3% in both trials. CONCLUSIONS: The addition of @entity1311 to @entity2033 - @entity3549 dose level 6 as first-line therapy was associated with a moderately elevated @entity137 . No substantial impact on survival can be anticipated for @entity2033 - @entity3549 +T. No significant financial relationships to disclose.

title: The role of XXXX in the first-line treatment of @entity1 with 'poor prognosis' @entity2971 ( @entity2971 ) undergoing sequential high dose chemotherapy.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity3136 :: ('MESH:D013280', 'Disease') :: ['stomatitis']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity1311 :: ('MESH:D017239', 'Chemical') :: ['Paclitaxel', 'paclitaxel']

entities_list: @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['manifest infection']

entities_list: @entity1260 :: ('MESH:D007069', 'Chemical') :: ['ifosfamide']

entities_list: @entity221 :: ('MESH:D005334', 'Disease') :: ['neutropenic fever']

answer: @entity1311 :: (MESH:D017239,Chemical) :: ['paclitaxel']


abstract: UNASSIGNED: 4633 Background: @entity1311 (T) has shown significant activity both in @entity900 -refractory and untreated @entity2971 @entity1 (pts). In order to determine the impact of T on survival (OS) and @entity137 the analysis compares the results of two prospective trials in pts with 'poor prognosis' @entity2971 . METHODS: In the first trial pts have received high dose @entity3549 chemotherapy ( @entity2033 - @entity3549 ) at dose level [ @entity2879 250 mg/sqm, @entity1260 2 g/sqm, @entity900 20 mg/sqm, d1-5, q d22] for 3 consecutive cycles as part of a phase I/II dose trial. Pts received G-CSF 5  g/kg s.c. from d+1 after treatment to leukocyte recovery >2000/ l and reinfusion of PBSC at day +2. The comparative trial consisted of pts treated in an identical fashion but additionally receiving T at a dose of 225 mg/sqm added on day 1 as a 3-h infusion prior to @entity900 ( @entity2033 - @entity3549 +T. RESULTS: 155 pts have been analyzed, 59 pts in @entity2033 - @entity3549 and 96 pts in @entity2033 - @entity3549 +T. 112 pts and 414 cycles are fully assessable for @entity137 , 152 pts for OS. Pts characteristics ( @entity2033 - @entity3549 compared to HDVIP+T): Median age 29 (16-42) vs. 31 yrs (18-54), mediastinal primary 11 vs. 24%, liver mets 40 vs. 40%, bone 7 vs. 4%, CNS 20 vs. 19%, elevated AFP, @entity6740 , LDH: 39 vs. 30%, 61 vs. 58% and 77 vs. 77%. Dose intensity of the 3- vs. 4-drug regimen achieved have been 98% and 95%. Median time to recovery of granulocytes and thrombocytes (>500/ l resp. >25.000 l) have been day 15 and 16 independent from the addition of T. Differences in grade III/IV @entity137 in favor of @entity2033 - @entity3549 were seen in terms of @entity3136 (14 vs. 49%), @entity221 (3 vs. 20%) and @entity281 (3 vs. 19%) (P.05). 88% of pts attained a favorable response (NED/CR/PRm-) to @entity2033 - @entity3549 compared to 67% in the @entity2033 - @entity3549 +T (P<.05). After a median follow up period of 34 mos (range, 9-78) and 16 (0-47) the calculated 3-yr OS rates were 69.9 (CI95%, 54.3-83.3) for @entity2033 - @entity3549 and 67.3% (56.3-78.3) for @entity2033 - @entity3549 +T (P=.3). Early death rate due to progression/ @entity137 was 3% in both trials. CONCLUSIONS: The addition of @entity1311 to @entity2033 - @entity3549 dose level 6 as first-line therapy was associated with a moderately elevated @entity137 . No substantial impact on survival can be anticipated for @entity2033 - @entity3549 +T. No significant financial relationships to disclose.

title: The role of @entity1311 in the first-line treatment of @entity1 with 'poor prognosis' XXXX ( @entity2971 ) undergoing sequential high dose chemotherapy.

answer: @entity2971 :: (MESH:D009373,Disease) :: ['germ cell tumor']


abstract: UNASSIGNED: 4633 Background: @entity1311 (T) has shown significant activity both in @entity900 -refractory and untreated @entity2971 @entity1 (pts). In order to determine the impact of T on survival (OS) and @entity137 the analysis compares the results of two prospective trials in pts with 'poor prognosis' @entity2971 . METHODS: In the first trial pts have received high dose @entity3549 chemotherapy ( @entity2033 - @entity3549 ) at dose level [ @entity2879 250 mg/sqm, @entity1260 2 g/sqm, @entity900 20 mg/sqm, d1-5, q d22] for 3 consecutive cycles as part of a phase I/II dose trial. Pts received G-CSF 5  g/kg s.c. from d+1 after treatment to leukocyte recovery >2000/ l and reinfusion of PBSC at day +2. The comparative trial consisted of pts treated in an identical fashion but additionally receiving T at a dose of 225 mg/sqm added on day 1 as a 3-h infusion prior to @entity900 ( @entity2033 - @entity3549 +T. RESULTS: 155 pts have been analyzed, 59 pts in @entity2033 - @entity3549 and 96 pts in @entity2033 - @entity3549 +T. 112 pts and 414 cycles are fully assessable for @entity137 , 152 pts for OS. Pts characteristics ( @entity2033 - @entity3549 compared to HDVIP+T): Median age 29 (16-42) vs. 31 yrs (18-54), mediastinal primary 11 vs. 24%, liver mets 40 vs. 40%, bone 7 vs. 4%, CNS 20 vs. 19%, elevated AFP, @entity6740 , LDH: 39 vs. 30%, 61 vs. 58% and 77 vs. 77%. Dose intensity of the 3- vs. 4-drug regimen achieved have been 98% and 95%. Median time to recovery of granulocytes and thrombocytes (>500/ l resp. >25.000 l) have been day 15 and 16 independent from the addition of T. Differences in grade III/IV @entity137 in favor of @entity2033 - @entity3549 were seen in terms of @entity3136 (14 vs. 49%), @entity221 (3 vs. 20%) and @entity281 (3 vs. 19%) (P.05). 88% of pts attained a favorable response (NED/CR/PRm-) to @entity2033 - @entity3549 compared to 67% in the @entity2033 - @entity3549 +T (P<.05). After a median follow up period of 34 mos (range, 9-78) and 16 (0-47) the calculated 3-yr OS rates were 69.9 (CI95%, 54.3-83.3) for @entity2033 - @entity3549 and 67.3% (56.3-78.3) for @entity2033 - @entity3549 +T (P=.3). Early death rate due to progression/ @entity137 was 3% in both trials. CONCLUSIONS: The addition of @entity1311 to @entity2033 - @entity3549 dose level 6 as first-line therapy was associated with a moderately elevated @entity137 . No substantial impact on survival can be anticipated for @entity2033 - @entity3549 +T. No significant financial relationships to disclose.

title: The role of @entity1311 in the first-line treatment of @entity1 with 'poor prognosis' @entity2971 ( XXXX ) undergoing sequential high dose chemotherapy.

answer: @entity2971 :: (MESH:D009373,Disease) :: ['GCT']


abstract: UNASSIGNED: 4633 Background: @entity1311 (T) has shown significant activity both in @entity900 -refractory and untreated @entity2971 @entity1 (pts). In order to determine the impact of T on survival (OS) and @entity137 the analysis compares the results of two prospective trials in pts with 'poor prognosis' @entity2971 . METHODS: In the first trial pts have received high dose @entity3549 chemotherapy ( @entity2033 - @entity3549 ) at dose level [ @entity2879 250 mg/sqm, @entity1260 2 g/sqm, @entity900 20 mg/sqm, d1-5, q d22] for 3 consecutive cycles as part of a phase I/II dose trial. Pts received G-CSF 5  g/kg s.c. from d+1 after treatment to leukocyte recovery >2000/ l and reinfusion of PBSC at day +2. The comparative trial consisted of pts treated in an identical fashion but additionally receiving T at a dose of 225 mg/sqm added on day 1 as a 3-h infusion prior to @entity900 ( @entity2033 - @entity3549 +T. RESULTS: 155 pts have been analyzed, 59 pts in @entity2033 - @entity3549 and 96 pts in @entity2033 - @entity3549 +T. 112 pts and 414 cycles are fully assessable for @entity137 , 152 pts for OS. Pts characteristics ( @entity2033 - @entity3549 compared to HDVIP+T): Median age 29 (16-42) vs. 31 yrs (18-54), mediastinal primary 11 vs. 24%, liver mets 40 vs. 40%, bone 7 vs. 4%, CNS 20 vs. 19%, elevated AFP, @entity6740 , LDH: 39 vs. 30%, 61 vs. 58% and 77 vs. 77%. Dose intensity of the 3- vs. 4-drug regimen achieved have been 98% and 95%. Median time to recovery of granulocytes and thrombocytes (>500/ l resp. >25.000 l) have been day 15 and 16 independent from the addition of T. Differences in grade III/IV @entity137 in favor of @entity2033 - @entity3549 were seen in terms of @entity3136 (14 vs. 49%), @entity221 (3 vs. 20%) and @entity281 (3 vs. 19%) (P.05). 88% of pts attained a favorable response (NED/CR/PRm-) to @entity2033 - @entity3549 compared to 67% in the @entity2033 - @entity3549 +T (P<.05). After a median follow up period of 34 mos (range, 9-78) and 16 (0-47) the calculated 3-yr OS rates were 69.9 (CI95%, 54.3-83.3) for @entity2033 - @entity3549 and 67.3% (56.3-78.3) for @entity2033 - @entity3549 +T (P=.3). Early death rate due to progression/ @entity137 was 3% in both trials. CONCLUSIONS: The addition of @entity1311 to @entity2033 - @entity3549 dose level 6 as first-line therapy was associated with a moderately elevated @entity137 . No substantial impact on survival can be anticipated for @entity2033 - @entity3549 +T. No significant financial relationships to disclose.

title: The role of @entity1311 in the first-line treatment of XXXX with 'poor prognosis' @entity2971 ( @entity2971 ) undergoing sequential high dose chemotherapy.

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: UNASSIGNED: 8008 Background: @entity3136 ( @entity3136 ) limits chemotherapy dosing and increases health care costs. AES-14 (Saforis) enhances direct oral mucosal cell uptake of @entity9640 by the Aesgen UpTec system. Prior AES-14 studies in chemotherapy @entity1 suggested safe, effective reduction (20%) of clinically significant @entity3136 . METHODS: A randomized, double-blind, placebo-controlled crossover multicenter trial was conducted in @entity0 @entity1 receiving at least 3 cycles of an @entity5948 regimen (AC, CAF or @entity7366 ). @entity1 developing WHO Grade (Gr) 2-4 @entity3136 during screening cycle were randomized for crossover in 2 subsequent cycles. Study drug began 1st day of chemotherapy and continued 14 days after last chemotherapy dose or 5 days after @entity3136 resolved. Safety was assessed by Adverse Event (AE)/Serious AE evaluations. Primary endpoint analysis compared proportion of @entity1 with >=  Gr 2 @entity3136 while on AES-14 versus placebo. Secondary endpoints included @entity3136 duration and @entity3136 Assessment Scale outcomes. RESULTS: 2,064 female @entity1 were screened for @entity3136 >=  WHO Gr 2. 326 @entity1 (mean age 51 years) were randomized (15.7% @entity3136 rate). Peak @entity3136 was primarily WHO Gr 2. No significant randomization imbalances occurred. Comparison of treatment versus placebo outcomes in crossover design requires that no significant drug treatment carryover effect exists. AES-14 administered during 1st treatment cycle reduced >=  Gr 2 @entity3136 incidence in the placebo 2nd treatment cycle (p=0.0269). This carryover effect invalidated crossover efficacy comparison. Primary endpoint analysis thus compared parallel group treatment during 1st cycle only. Incidence of clinically significant @entity3136 (WHO Gr 2-4) was 22% less with AES-14 versus placebo (p=0.0261). No AES-14-related SAEs and 2 placebo-associated SAEs were reported. CONCLUSIONS: AES-14 reduced incidence of 1st cycle Gr 2-4 @entity3136 by 22% in these chemotherapy @entity1 . The significant AES-14 carryover effect suggests that optimizing mucosal repair during one cycle may protect @entity1 from @entity3136 during subsequent chemotherapy. Supported by Aesgen Inc. [Table: see text].

title: Phase III study: AES-14 in @entity1 at risk for mucositis secondary to XXXX -based chemotherapy.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity3136 :: ('MESH:D013280', 'Disease') :: ['OM', 'Oral mucositis']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast carcinoma']

entities_list: @entity5948 :: ('D018943', 'Chemical') :: ['anthracycline']

entities_list: @entity9640 :: ('CHEBI:18050', 'Chemical') :: ['L-glutamine']

answer: @entity5948 :: (D018943,Chemical) :: ['anthracycline']


abstract: UNASSIGNED: 8008 Background: @entity3136 ( @entity3136 ) limits chemotherapy dosing and increases health care costs. AES-14 (Saforis) enhances direct oral mucosal cell uptake of @entity9640 by the Aesgen UpTec system. Prior AES-14 studies in chemotherapy @entity1 suggested safe, effective reduction (20%) of clinically significant @entity3136 . METHODS: A randomized, double-blind, placebo-controlled crossover multicenter trial was conducted in @entity0 @entity1 receiving at least 3 cycles of an @entity5948 regimen (AC, CAF or @entity7366 ). @entity1 developing WHO Grade (Gr) 2-4 @entity3136 during screening cycle were randomized for crossover in 2 subsequent cycles. Study drug began 1st day of chemotherapy and continued 14 days after last chemotherapy dose or 5 days after @entity3136 resolved. Safety was assessed by Adverse Event (AE)/Serious AE evaluations. Primary endpoint analysis compared proportion of @entity1 with >=  Gr 2 @entity3136 while on AES-14 versus placebo. Secondary endpoints included @entity3136 duration and @entity3136 Assessment Scale outcomes. RESULTS: 2,064 female @entity1 were screened for @entity3136 >=  WHO Gr 2. 326 @entity1 (mean age 51 years) were randomized (15.7% @entity3136 rate). Peak @entity3136 was primarily WHO Gr 2. No significant randomization imbalances occurred. Comparison of treatment versus placebo outcomes in crossover design requires that no significant drug treatment carryover effect exists. AES-14 administered during 1st treatment cycle reduced >=  Gr 2 @entity3136 incidence in the placebo 2nd treatment cycle (p=0.0269). This carryover effect invalidated crossover efficacy comparison. Primary endpoint analysis thus compared parallel group treatment during 1st cycle only. Incidence of clinically significant @entity3136 (WHO Gr 2-4) was 22% less with AES-14 versus placebo (p=0.0261). No AES-14-related SAEs and 2 placebo-associated SAEs were reported. CONCLUSIONS: AES-14 reduced incidence of 1st cycle Gr 2-4 @entity3136 by 22% in these chemotherapy @entity1 . The significant AES-14 carryover effect suggests that optimizing mucosal repair during one cycle may protect @entity1 from @entity3136 during subsequent chemotherapy. Supported by Aesgen Inc. [Table: see text].

title: Phase III study: AES-14 in XXXX at risk for mucositis secondary to @entity5948 -based chemotherapy.

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: UNASSIGNED: 7569 Background: The combination of Interferon a-2b (INF) and intravenous @entity1199 ( @entity1199 ) with chemotherapy (CT) has produced encouraging results in @entity320 , as shown in phase II and III trials, but @entity137 remains of concern. We report on our experience with a chemo-immunotherapy regimen with subcutaneous administration of @entity1199 . @entity1 AND METHODS: 28 @entity1 (pts) with advanced @entity320 , median age 47.5 years (range 29-70) and male/female ratio 19/9, received CT plus immunotherapy with subcutaneous @entity1199 and INF. Doses were as follows: @entity900 20 mg/m2 iv days 1-4, @entity5713 1.6 mg/m2 iv days 1-4, @entity2699 800 mg/m2 iv day 1, Interferon a-2b 5M IU/m2 sc days 1-5, @entity1199 9M IU sc days 1-5 and 8-12. Treatment was repeated every three weeks up to a maximum of six cycles. Response was assessed every two cycles and @entity137 every cycle, according to WHO and NCI criteria respectively. RESULTS: The overall response rate was 33% with 3 (11%) complete responses, lasting for 17, 14 and 24+ months respectively. There were 6 (22%) partial responses and 3 stable disease. 3 responders progressed in the central nervous system (CNS). For the whole population, median time to progression and survival were 3.5 and 9 months respectively. The most common G3-4 @entity137 was @entity1398 , reported in 25/28 (92%) pts. Only 2 pts (7%) experienced @entity221 . Less frequent was G3-4 @entity882 , observed in 6/28 (21%) pts, with only 1 pt needing platelet support. @entity1209 as well as fever following cytokine injections were reported in all pts. 1 toxic @entity204 occurred, due to @entity221 . CONCLUSIONS: This schedule with sc @entity1199 had an acceptable level of @entity137 and although the response rate was lower, @entity2106 and @entity3012 were comparable to those reported with more intensive regimens. Several pts progressed in the CNS, suggesting that new combinations able to prevent this event are needed. No significant financial relationships to disclose.

title: Combined chemo-immunotherapy for XXXX . A monoinstitutional experience.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity2699 :: ('MESH:D003606', 'Chemical') :: ['Dacarbazine']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['Cisplatinum']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma', 'metastatic melanoma']

entities_list: @entity5713 :: ('MESH:D014747', 'Chemical') :: ['Vinblastine']

entities_list: @entity1209 :: ('MESH:D020250', 'Disease') :: ['G1-2 nausea and vomiting']

answer: @entity320 :: (MESH:D008545,Disease) :: ['metastatic melanoma']


abstract: UNASSIGNED: 8099 Background: Chemotherapy-induced @entity2588 frequently results in side effects common to those experienced in menopause; @entity2133 ( @entity2133 ) and its related symptoms are prominent examples. Although many of these side effects respond to the use of @entity172 replacement therapy (ERT), many @entity5 survivors choose to not chance the risks linked with ERT. Previous results in a placebo-controlled Phase III study treating xeroses associated with @entity244 with oral @entity2134 (OP){Salagen   Tablets}demonstrated impressive improvement in @entity2133 , P<= 0.02 (25% vs.14%):Vivino et al; Arch Intern Med. 1999;159. METHODS: A 12-week, open-label pilot study was conducted using OP (5mg./qid) in pre-menopausal @entity1 with @entity2133 caused by the effects of high cumulative dose @entity786 on ovarian function. Study enrollment required a minimum 2 month history of @entity2133 and 4 months status-post chemotherapy. The primary endpoint of this study was a global assessment of @entity2133 measured on a standard visual analog scale (VAS), at 6 and 12 weeks of treatment, or at final study visit if prior to week 12. @entity1 were asked to characterize their @entity2133 at these visits compared to their @entity2133 before treatment with OP; each @entity1 acted as her own control. RESULTS: The pre-study expectation was for a 25 mm (absolute) improvement in the @entity1 ' VAS by end of study. Four of four evaluable @entity1 treated with OP experienced a marked clinical improvement in @entity2133 .Three responders recorded >= 40mm absolute gain in VAS, the fourth gained >= 28mm. CONCLUSIONS: OP, a well-tolerated muscarinic agonist was able to stimulate remaining mucus and other moisture producing cells in the vaginal mucosa _ muscularis to the extent that a marked clinical improvement in @entity2133 was experienced by each of the study @entity1 . The only AEs experienced were mild and of the known side effects of OP and did not interfere with treatment. These results warrant further investigation as a possible treatment for symptomatic relief of this difficult problem. No significant financial relationships to disclose.

title: Oral @entity2134 to treat vaginal xerosis associated with chemotherapy-induced XXXX in pre-menopausal @entity1 .

entities_list: @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen']

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'women', 'participant', 'Participants']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity2133 :: ('MESH:D014987', 'Disease') :: ['vaginal dryness', 'VD']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity2134 :: ('MESH:D010862', 'Chemical') :: ['pilocarpine']

entities_list: @entity244 :: ('MESH:D014899', 'Disease') :: ["Sj  gren's syndrome"]

entities_list: @entity2588 :: ('MESH:D000568', 'Disease') :: ['amenorrhea']

answer: @entity2588 :: (MESH:D000568,Disease) :: ['amenorrhea']


abstract: UNASSIGNED: 8099 Background: Chemotherapy-induced @entity2588 frequently results in side effects common to those experienced in menopause; @entity2133 ( @entity2133 ) and its related symptoms are prominent examples. Although many of these side effects respond to the use of @entity172 replacement therapy (ERT), many @entity5 survivors choose to not chance the risks linked with ERT. Previous results in a placebo-controlled Phase III study treating xeroses associated with @entity244 with oral @entity2134 (OP){Salagen   Tablets}demonstrated impressive improvement in @entity2133 , P<= 0.02 (25% vs.14%):Vivino et al; Arch Intern Med. 1999;159. METHODS: A 12-week, open-label pilot study was conducted using OP (5mg./qid) in pre-menopausal @entity1 with @entity2133 caused by the effects of high cumulative dose @entity786 on ovarian function. Study enrollment required a minimum 2 month history of @entity2133 and 4 months status-post chemotherapy. The primary endpoint of this study was a global assessment of @entity2133 measured on a standard visual analog scale (VAS), at 6 and 12 weeks of treatment, or at final study visit if prior to week 12. @entity1 were asked to characterize their @entity2133 at these visits compared to their @entity2133 before treatment with OP; each @entity1 acted as her own control. RESULTS: The pre-study expectation was for a 25 mm (absolute) improvement in the @entity1 ' VAS by end of study. Four of four evaluable @entity1 treated with OP experienced a marked clinical improvement in @entity2133 .Three responders recorded >= 40mm absolute gain in VAS, the fourth gained >= 28mm. CONCLUSIONS: OP, a well-tolerated muscarinic agonist was able to stimulate remaining mucus and other moisture producing cells in the vaginal mucosa _ muscularis to the extent that a marked clinical improvement in @entity2133 was experienced by each of the study @entity1 . The only AEs experienced were mild and of the known side effects of OP and did not interfere with treatment. These results warrant further investigation as a possible treatment for symptomatic relief of this difficult problem. No significant financial relationships to disclose.

title: Oral XXXX to treat vaginal xerosis associated with chemotherapy-induced @entity2588 in pre-menopausal @entity1 .

answer: @entity2134 :: (MESH:D010862,Chemical) :: ['pilocarpine']


abstract: UNASSIGNED: 8099 Background: Chemotherapy-induced @entity2588 frequently results in side effects common to those experienced in menopause; @entity2133 ( @entity2133 ) and its related symptoms are prominent examples. Although many of these side effects respond to the use of @entity172 replacement therapy (ERT), many @entity5 survivors choose to not chance the risks linked with ERT. Previous results in a placebo-controlled Phase III study treating xeroses associated with @entity244 with oral @entity2134 (OP){Salagen   Tablets}demonstrated impressive improvement in @entity2133 , P<= 0.02 (25% vs.14%):Vivino et al; Arch Intern Med. 1999;159. METHODS: A 12-week, open-label pilot study was conducted using OP (5mg./qid) in pre-menopausal @entity1 with @entity2133 caused by the effects of high cumulative dose @entity786 on ovarian function. Study enrollment required a minimum 2 month history of @entity2133 and 4 months status-post chemotherapy. The primary endpoint of this study was a global assessment of @entity2133 measured on a standard visual analog scale (VAS), at 6 and 12 weeks of treatment, or at final study visit if prior to week 12. @entity1 were asked to characterize their @entity2133 at these visits compared to their @entity2133 before treatment with OP; each @entity1 acted as her own control. RESULTS: The pre-study expectation was for a 25 mm (absolute) improvement in the @entity1 ' VAS by end of study. Four of four evaluable @entity1 treated with OP experienced a marked clinical improvement in @entity2133 .Three responders recorded >= 40mm absolute gain in VAS, the fourth gained >= 28mm. CONCLUSIONS: OP, a well-tolerated muscarinic agonist was able to stimulate remaining mucus and other moisture producing cells in the vaginal mucosa _ muscularis to the extent that a marked clinical improvement in @entity2133 was experienced by each of the study @entity1 . The only AEs experienced were mild and of the known side effects of OP and did not interfere with treatment. These results warrant further investigation as a possible treatment for symptomatic relief of this difficult problem. No significant financial relationships to disclose.

title: Oral @entity2134 to treat vaginal xerosis associated with chemotherapy-induced @entity2588 in pre-menopausal XXXX .

answer: @entity1 :: (9606,Species) :: ['women']


abstract: OBJECTIVES: Neonates with @entity299 are at risk for @entity75 . Little is known about the further evolution of cerebral abnormalities until Fontan procedure. METHODS: Between August 2012 and July 2015, we conducted a prospective cross-sectional two centre study using cerebral magnetic resonance imaging (MRI) and neuro-developmental outcome assessed by the Bayley-III. Forty-seven @entity1 (31 male) were evaluated at a mean age of 25.9        3.4 months with @entity1699 (25) or other single ventricle (22). RESULTS: Cerebral MRI was abnormal in 17 @entity1 (36.2%) including liquor space enlargements (10), small grey (9) and minimal white (5) matter injuries. Eight of 17 individuals had combined lesions. Median (range) cognitive composite score (CCS) (100, 65-120) and motor composite score (MCS) (97, 55-124) were comparable to the reference data, while language composite score (LCS) (97, 68-124) was significantly lower (P   =   0.040). Liquor space enlargement was associated with poorer performance on all Bayley-III subscores (CCS: P   =   0.02; LCS: P   =   0.002; MCS: P   =   0.013). The number of re-operations [odds ratio (OR) 2.2, 95% confidence interval (CI) 1.1-4.3] (P   =   0.03) and re-interventions (OR 2.1, 95% CI 1.1-3.8) (P   =   0.03) was associated with a higher rate of @entity854 . CONCLUSIONS: @entity75 occur in more than one third of @entity1 with single ventricle, while the neuro-developmental status is less severely affected before Fontan procedure. Liquor space enlargement is the predominant MRI finding associated with poorer neuro-developmental status, warranting further studies to determine aetiology and further evolution until school-age.

title: @entity75 and neurodevelopmental status in XXXX before Fontan procedure.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['Cerebral MRI abnormalities', 'structural cerebral abnormalities']

entities_list: @entity1699 :: ('MESH:D018636', 'Disease') :: ['hypoplastic left heart syndrome']

entities_list: @entity854 :: ('MESH:D018376', 'Disease') :: ['overall MRI abnormalities']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['single ventricle congenital heart disease']

answer: @entity299 :: (MESH:D006331,Disease) :: ['single ventricle congenital heart disease']


abstract: OBJECTIVES: Neonates with @entity299 are at risk for @entity75 . Little is known about the further evolution of cerebral abnormalities until Fontan procedure. METHODS: Between August 2012 and July 2015, we conducted a prospective cross-sectional two centre study using cerebral magnetic resonance imaging (MRI) and neuro-developmental outcome assessed by the Bayley-III. Forty-seven @entity1 (31 male) were evaluated at a mean age of 25.9        3.4 months with @entity1699 (25) or other single ventricle (22). RESULTS: Cerebral MRI was abnormal in 17 @entity1 (36.2%) including liquor space enlargements (10), small grey (9) and minimal white (5) matter injuries. Eight of 17 individuals had combined lesions. Median (range) cognitive composite score (CCS) (100, 65-120) and motor composite score (MCS) (97, 55-124) were comparable to the reference data, while language composite score (LCS) (97, 68-124) was significantly lower (P   =   0.040). Liquor space enlargement was associated with poorer performance on all Bayley-III subscores (CCS: P   =   0.02; LCS: P   =   0.002; MCS: P   =   0.013). The number of re-operations [odds ratio (OR) 2.2, 95% confidence interval (CI) 1.1-4.3] (P   =   0.03) and re-interventions (OR 2.1, 95% CI 1.1-3.8) (P   =   0.03) was associated with a higher rate of @entity854 . CONCLUSIONS: @entity75 occur in more than one third of @entity1 with single ventricle, while the neuro-developmental status is less severely affected before Fontan procedure. Liquor space enlargement is the predominant MRI finding associated with poorer neuro-developmental status, warranting further studies to determine aetiology and further evolution until school-age.

title: XXXX and neurodevelopmental status in @entity299 before Fontan procedure.

answer: @entity75 :: (MESH:D001927,Disease) :: ['Structural cerebral abnormalities']


abstract: UNASSIGNED: @entity2743 ( @entity2743 ) and @entity2621 ( @entity2621 ) are @entity1669 ( @entity1669 ). Prognosis of @entity1669 varies in each @entity1 . Toll-like receptors (TLRs) are pattern-recognition receptors that activate signaling pathways involved in the production of proinflammatory cytokines. @entity38465 is a transcription factor of @entity6438 and @entity6801 . In this study, we examined the association of TLR expression and TLR and @entity38465 polymorphisms with the development and prognosis of @entity1669 . The ratio of intracellular @entity6438 (iTLR7) and iTLR9 intensities in B cells was lower in @entity1 with @entity2743 in remission than in @entity1 with intractable @entity2743 (p   =   0.0007). The frequency of G allele of @entity6438 @entity72206   @entity9063 polymorphism was significantly higher in male @entity1 with @entity2743 and intractable @entity2743 than in control subjects (p   =   0.0062 and 0.0173, respectively). The frequencies of T allele of @entity6801 @entity15933 @entity6344 polymorphism and C allele of @entity6801 @entity64800 @entity6344 polymorphism were significantly higher in @entity1 with intractable @entity2743 who had GG genotype of @entity6438 @entity72206 polymorphism, which is associated with higher @entity6438 expression, than in @entity1 with @entity2743 in remission (p   =   0.0334 and 0.0023, respectively). The frequencies of AA genotype and A allele of @entity38465 @entity72207 polymorphism were significantly higher in @entity1 with @entity2743 than in @entity1 with @entity2621 (p   =   0.0406 and 0.0316, respectively). These results suggested that the ratio of iTLR7 and iTLR9 intensities was associated with the development and intractability of @entity2743 and that @entity6438 and @entity38465 polymorphisms were associated with the development of @entity2743 .

title: Polymorphisms and expression of toll-like receptors in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity9063 :: ('c|SUB|G||C', 'DNAMutation') :: ['G/C']

entities_list: @entity6344 :: ('c|SUB|C||T', 'DNAMutation') :: ['C/T']

entities_list: @entity2743 :: ('MESH:D006111', 'Disease') :: ["Graves' disease", 'GD']

entities_list: @entity2621 :: ('MESH:D050031', 'Disease') :: ["Hashimoto's disease", 'HD']

entities_list: @entity1669 :: ('MESH:D013967', 'Disease') :: ['autoimmune thyroid diseases', 'AITDs']

answer: @entity1669 :: (MESH:D013967,Disease) :: ['autoimmune thyroid diseases']


abstract: PURPOSE: To identify clinical incidence, risk factors and treatment of peripherally inserted central venous catheters (PICCs)-related @entity49 ( @entity49 ) in @entity0 @entity1 undergoing chemotherapy. METHODS: We performed a retrospective cohort study of @entity0 @entity1 with PICC insertion undergoing chemotherapy. PICC-related @entity49 was diagnosed by ultrasound. @entity1 -, catheter- and insertion-related factors were analyzed in univariable and multivariable logistic regression to identify significant independent risk factors for PICC-related @entity49 . The incidence and treatment of PICC-related @entity49 were also analyzed. RESULTS: A total of 568 @entity0 @entity1 with PICC undergoing chemotherapy were included, for a total of 54,769 catheter days; 8 @entity1 (1.4%) developed PICC-related @entity49 . The median time of developing @entity49 was 11 days (range of 3 to 79 days). In multivariable analysis, @entity3 (p = 0.002) and malposition (p = 0.013) were shown to be significant risk factors for PICC-related @entity49 . All @entity1 were treated with low-molecular-weight heparin (LMWH) and followed until PICCs were removed. None of the @entity1 developed @entity358 . CONCLUSIONS: @entity3 and malposition were significant risk factors for PICC-related @entity49 in @entity0 @entity1 . With early diagnosis and standardized anticoagulant treatment, a better clinical outcome could be achieved. Further prospective and large sample studies are needed.

title: Peripherally inserted central catheter-related vein thrombosis in XXXX @entity1 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Patient']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity49 :: ('MESH:D019851', 'Disease') :: ['UEVT', 'upper extremity venous thrombosis']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary embolus']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis', 'Metastasis']

answer: @entity0 :: (MESH:D001943,Disease) :: ['breast cancer']


abstract: PURPOSE: To identify clinical incidence, risk factors and treatment of peripherally inserted central venous catheters (PICCs)-related @entity49 ( @entity49 ) in @entity0 @entity1 undergoing chemotherapy. METHODS: We performed a retrospective cohort study of @entity0 @entity1 with PICC insertion undergoing chemotherapy. PICC-related @entity49 was diagnosed by ultrasound. @entity1 -, catheter- and insertion-related factors were analyzed in univariable and multivariable logistic regression to identify significant independent risk factors for PICC-related @entity49 . The incidence and treatment of PICC-related @entity49 were also analyzed. RESULTS: A total of 568 @entity0 @entity1 with PICC undergoing chemotherapy were included, for a total of 54,769 catheter days; 8 @entity1 (1.4%) developed PICC-related @entity49 . The median time of developing @entity49 was 11 days (range of 3 to 79 days). In multivariable analysis, @entity3 (p = 0.002) and malposition (p = 0.013) were shown to be significant risk factors for PICC-related @entity49 . All @entity1 were treated with low-molecular-weight heparin (LMWH) and followed until PICCs were removed. None of the @entity1 developed @entity358 . CONCLUSIONS: @entity3 and malposition were significant risk factors for PICC-related @entity49 in @entity0 @entity1 . With early diagnosis and standardized anticoagulant treatment, a better clinical outcome could be achieved. Further prospective and large sample studies are needed.

title: Peripherally inserted central catheter-related vein thrombosis in @entity0 XXXX .

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: UNASSIGNED: 724 Background: @entity1 (pts) with @entity0 often receive intensive chemotherapy to halt disease progression. Subsequent treatment choices are thus complex due to cumulative @entity137 of previous therapies, to paucity of effective cytotoxic regimens with a low @entity137 burden, and to compromised performance status. METHODS: A combination of @entity3003 (AUC4, Calvert) plus @entity8178 (1250 mg/m(2) Days 1 _ 8, than reduced to 1000 mg/m(2) ) was given to 28 pts with @entity0 (median age: 50 yrs, range: 31-72; PS 0-1/2: 25/3). All @entity1 previously received chemotherapy for metastatic disease, 21 had >=  3 chemotherapy regimens; 11 pts had disease resistant to both @entity5948 and @entity6023 . RESULTS: After the first 4 pts were treated, @entity8178 -dose was reduced from 1250 to 1000 mg/m(2) because of limiting haematological @entity137 on day 1 or 8, requiring treatment delay/omission: @entity1398 G3 (2 pt) / G4 (1 pt), @entity882 G4 (1 pt), @entity417 G3 (1 pt). After @entity8178 dose-reduction, we observed G3-4 @entity882 (21%,) and @entity1398 (50%), with 1 episode of @entity1398 not requiring hospitalisation. Subjective @entity137 was mild, without non-haematolgical G3-4 @entity137 but G3 skin-reaction (3 pts). Partial responses were observed in 5/23 pts valuable (22%); stable disease and disease progression in 7 and 12 pts, respectively. Two @entity1 with partial responses and 2 with disease stabilisation were observed in the 11 pts resistant to both @entity6023 and @entity5948 . CONCLUSIONS: This regimen is effective and well-tolerated and might be considered a reasonable treatment option for heavily pretreated @entity1 . No significant financial relationships to disclose.

title: Caring for heavily pretreated @entity1 with @entity0 ( @entity0 ): XXXX ( @entity3003 ) - gemcitabine ( @entity8178 ) combination is effective and well tolerate.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity5948 :: ('D018943', 'Chemical') :: ['anthracycline']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'febrile neutropenia']

answer: @entity3003 :: (MESH:D016190,Chemical) :: ['Carboplatin']


abstract: UNASSIGNED: 724 Background: @entity1 (pts) with @entity0 often receive intensive chemotherapy to halt disease progression. Subsequent treatment choices are thus complex due to cumulative @entity137 of previous therapies, to paucity of effective cytotoxic regimens with a low @entity137 burden, and to compromised performance status. METHODS: A combination of @entity3003 (AUC4, Calvert) plus @entity8178 (1250 mg/m(2) Days 1 _ 8, than reduced to 1000 mg/m(2) ) was given to 28 pts with @entity0 (median age: 50 yrs, range: 31-72; PS 0-1/2: 25/3). All @entity1 previously received chemotherapy for metastatic disease, 21 had >=  3 chemotherapy regimens; 11 pts had disease resistant to both @entity5948 and @entity6023 . RESULTS: After the first 4 pts were treated, @entity8178 -dose was reduced from 1250 to 1000 mg/m(2) because of limiting haematological @entity137 on day 1 or 8, requiring treatment delay/omission: @entity1398 G3 (2 pt) / G4 (1 pt), @entity882 G4 (1 pt), @entity417 G3 (1 pt). After @entity8178 dose-reduction, we observed G3-4 @entity882 (21%,) and @entity1398 (50%), with 1 episode of @entity1398 not requiring hospitalisation. Subjective @entity137 was mild, without non-haematolgical G3-4 @entity137 but G3 skin-reaction (3 pts). Partial responses were observed in 5/23 pts valuable (22%); stable disease and disease progression in 7 and 12 pts, respectively. Two @entity1 with partial responses and 2 with disease stabilisation were observed in the 11 pts resistant to both @entity6023 and @entity5948 . CONCLUSIONS: This regimen is effective and well-tolerated and might be considered a reasonable treatment option for heavily pretreated @entity1 . No significant financial relationships to disclose.

title: Caring for heavily pretreated @entity1 with @entity0 ( @entity0 ): @entity3003 ( XXXX ) - gemcitabine ( @entity8178 ) combination is effective and well tolerate.

answer: @entity3003 :: (MESH:D016190,Chemical) :: ['CBDCA']


abstract: UNASSIGNED: 724 Background: @entity1 (pts) with @entity0 often receive intensive chemotherapy to halt disease progression. Subsequent treatment choices are thus complex due to cumulative @entity137 of previous therapies, to paucity of effective cytotoxic regimens with a low @entity137 burden, and to compromised performance status. METHODS: A combination of @entity3003 (AUC4, Calvert) plus @entity8178 (1250 mg/m(2) Days 1 _ 8, than reduced to 1000 mg/m(2) ) was given to 28 pts with @entity0 (median age: 50 yrs, range: 31-72; PS 0-1/2: 25/3). All @entity1 previously received chemotherapy for metastatic disease, 21 had >=  3 chemotherapy regimens; 11 pts had disease resistant to both @entity5948 and @entity6023 . RESULTS: After the first 4 pts were treated, @entity8178 -dose was reduced from 1250 to 1000 mg/m(2) because of limiting haematological @entity137 on day 1 or 8, requiring treatment delay/omission: @entity1398 G3 (2 pt) / G4 (1 pt), @entity882 G4 (1 pt), @entity417 G3 (1 pt). After @entity8178 dose-reduction, we observed G3-4 @entity882 (21%,) and @entity1398 (50%), with 1 episode of @entity1398 not requiring hospitalisation. Subjective @entity137 was mild, without non-haematolgical G3-4 @entity137 but G3 skin-reaction (3 pts). Partial responses were observed in 5/23 pts valuable (22%); stable disease and disease progression in 7 and 12 pts, respectively. Two @entity1 with partial responses and 2 with disease stabilisation were observed in the 11 pts resistant to both @entity6023 and @entity5948 . CONCLUSIONS: This regimen is effective and well-tolerated and might be considered a reasonable treatment option for heavily pretreated @entity1 . No significant financial relationships to disclose.

title: Caring for heavily pretreated @entity1 with XXXX ( @entity0 ): @entity3003 ( @entity3003 ) - gemcitabine ( @entity8178 ) combination is effective and well tolerate.

answer: @entity0 :: (MESH:D001943,Disease) :: ['metastatic breast cancer']


abstract: UNASSIGNED: 724 Background: @entity1 (pts) with @entity0 often receive intensive chemotherapy to halt disease progression. Subsequent treatment choices are thus complex due to cumulative @entity137 of previous therapies, to paucity of effective cytotoxic regimens with a low @entity137 burden, and to compromised performance status. METHODS: A combination of @entity3003 (AUC4, Calvert) plus @entity8178 (1250 mg/m(2) Days 1 _ 8, than reduced to 1000 mg/m(2) ) was given to 28 pts with @entity0 (median age: 50 yrs, range: 31-72; PS 0-1/2: 25/3). All @entity1 previously received chemotherapy for metastatic disease, 21 had >=  3 chemotherapy regimens; 11 pts had disease resistant to both @entity5948 and @entity6023 . RESULTS: After the first 4 pts were treated, @entity8178 -dose was reduced from 1250 to 1000 mg/m(2) because of limiting haematological @entity137 on day 1 or 8, requiring treatment delay/omission: @entity1398 G3 (2 pt) / G4 (1 pt), @entity882 G4 (1 pt), @entity417 G3 (1 pt). After @entity8178 dose-reduction, we observed G3-4 @entity882 (21%,) and @entity1398 (50%), with 1 episode of @entity1398 not requiring hospitalisation. Subjective @entity137 was mild, without non-haematolgical G3-4 @entity137 but G3 skin-reaction (3 pts). Partial responses were observed in 5/23 pts valuable (22%); stable disease and disease progression in 7 and 12 pts, respectively. Two @entity1 with partial responses and 2 with disease stabilisation were observed in the 11 pts resistant to both @entity6023 and @entity5948 . CONCLUSIONS: This regimen is effective and well-tolerated and might be considered a reasonable treatment option for heavily pretreated @entity1 . No significant financial relationships to disclose.

title: Caring for heavily pretreated @entity1 with @entity0 ( XXXX ): @entity3003 ( @entity3003 ) - gemcitabine ( @entity8178 ) combination is effective and well tolerate.

answer: @entity0 :: (MESH:D001943,Disease) :: ['MBC']


abstract: UNASSIGNED: 724 Background: @entity1 (pts) with @entity0 often receive intensive chemotherapy to halt disease progression. Subsequent treatment choices are thus complex due to cumulative @entity137 of previous therapies, to paucity of effective cytotoxic regimens with a low @entity137 burden, and to compromised performance status. METHODS: A combination of @entity3003 (AUC4, Calvert) plus @entity8178 (1250 mg/m(2) Days 1 _ 8, than reduced to 1000 mg/m(2) ) was given to 28 pts with @entity0 (median age: 50 yrs, range: 31-72; PS 0-1/2: 25/3). All @entity1 previously received chemotherapy for metastatic disease, 21 had >=  3 chemotherapy regimens; 11 pts had disease resistant to both @entity5948 and @entity6023 . RESULTS: After the first 4 pts were treated, @entity8178 -dose was reduced from 1250 to 1000 mg/m(2) because of limiting haematological @entity137 on day 1 or 8, requiring treatment delay/omission: @entity1398 G3 (2 pt) / G4 (1 pt), @entity882 G4 (1 pt), @entity417 G3 (1 pt). After @entity8178 dose-reduction, we observed G3-4 @entity882 (21%,) and @entity1398 (50%), with 1 episode of @entity1398 not requiring hospitalisation. Subjective @entity137 was mild, without non-haematolgical G3-4 @entity137 but G3 skin-reaction (3 pts). Partial responses were observed in 5/23 pts valuable (22%); stable disease and disease progression in 7 and 12 pts, respectively. Two @entity1 with partial responses and 2 with disease stabilisation were observed in the 11 pts resistant to both @entity6023 and @entity5948 . CONCLUSIONS: This regimen is effective and well-tolerated and might be considered a reasonable treatment option for heavily pretreated @entity1 . No significant financial relationships to disclose.

title: Caring for heavily pretreated @entity1 with @entity0 ( @entity0 ): @entity3003 ( @entity3003 ) - gemcitabine ( XXXX ) combination is effective and well tolerate.

answer: @entity8178 :: (CHEBI:74858,Chemical) :: ['GCB']


abstract: UNASSIGNED: 724 Background: @entity1 (pts) with @entity0 often receive intensive chemotherapy to halt disease progression. Subsequent treatment choices are thus complex due to cumulative @entity137 of previous therapies, to paucity of effective cytotoxic regimens with a low @entity137 burden, and to compromised performance status. METHODS: A combination of @entity3003 (AUC4, Calvert) plus @entity8178 (1250 mg/m(2) Days 1 _ 8, than reduced to 1000 mg/m(2) ) was given to 28 pts with @entity0 (median age: 50 yrs, range: 31-72; PS 0-1/2: 25/3). All @entity1 previously received chemotherapy for metastatic disease, 21 had >=  3 chemotherapy regimens; 11 pts had disease resistant to both @entity5948 and @entity6023 . RESULTS: After the first 4 pts were treated, @entity8178 -dose was reduced from 1250 to 1000 mg/m(2) because of limiting haematological @entity137 on day 1 or 8, requiring treatment delay/omission: @entity1398 G3 (2 pt) / G4 (1 pt), @entity882 G4 (1 pt), @entity417 G3 (1 pt). After @entity8178 dose-reduction, we observed G3-4 @entity882 (21%,) and @entity1398 (50%), with 1 episode of @entity1398 not requiring hospitalisation. Subjective @entity137 was mild, without non-haematolgical G3-4 @entity137 but G3 skin-reaction (3 pts). Partial responses were observed in 5/23 pts valuable (22%); stable disease and disease progression in 7 and 12 pts, respectively. Two @entity1 with partial responses and 2 with disease stabilisation were observed in the 11 pts resistant to both @entity6023 and @entity5948 . CONCLUSIONS: This regimen is effective and well-tolerated and might be considered a reasonable treatment option for heavily pretreated @entity1 . No significant financial relationships to disclose.

title: Caring for heavily pretreated XXXX with @entity0 ( @entity0 ): @entity3003 ( @entity3003 ) - gemcitabine ( @entity8178 ) combination is effective and well tolerate.

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: UNASSIGNED: 715 Background: Experience with chemotherapy for @entity0 during pregnancy is limited. This retrospective case series presents the accumulated experience of four London hospitals in giving chemotherapy to 28 pregnant @entity1 with @entity0 . This represents one of the largest series of such @entity1 to date. METHODS: A retrospective case note review was performed at four London hospitals to identify @entity1 who received chemotherapy for @entity0 whilst pregnant. RESULTS: Twenty-eight @entity1 were identified who had received chemotherapy for @entity0 whilst pregnant, with stage I (2), stage II (11), stage III (11) and stage IV disease (4). The mean maternal age at diagnosis was 34 years (range 28-42), the mean gestational age at diagnosis was 17 weeks (range 4-33). Seventeen @entity1 underwent surgery whilst pregnant, at a mean gestational age of 16 weeks (range 5-29). Chemotherapy was given in the adjuvant (17), neoadjuvant (7) and palliative settings (4). Sixteen @entity1 received @entity5948 -based chemotherapy, and 12 CMF. One @entity1 was treated in the first trimester, but had a @entity2208 . The remaining 27 @entity1 were treated in the second and third trimesters, commencing at a mean gestational age of 22.7 weeks (range 15-33). A total of 116 cycles of chemotherapy were given, with a median of 4 cycles during pregnancy (range 1-6). Chemotherapy was well tolerated at full doses without major complications. The mean gestational age at delivery was 37 weeks (range 30-40). No @entity600 were reported, and the mean birth weight of the @entity1 was 2.9kg (range 1.4 to 3.5). Two of the newborns experienced @entity649 and a total of 5 required transfer to a specialised neonatal unit, but all made full recoveries. CONCLUSIONS: In terms of peri-partum complications and immediate fetal outcome, chemotherapy can be safely administered to @entity1 with @entity0 in the second and third trimesters of pregnancy. No significant financial relationships to disclose.

title: Chemotherapy for XXXX given during pregnancy: A case serie.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient', 'infants']

entities_list: @entity2208 :: ('MESH:D000022', 'Disease') :: ['spontaneous abortion']

entities_list: @entity649 :: ('MESH:D012128', 'Disease') :: ['respiratory distress']

entities_list: @entity600 :: ('MESH:D000014', 'Disease') :: ['congenital malformations']

answer: @entity0 :: (MESH:D001943,Disease) :: ['breast cancer']


abstract: UNASSIGNED: 7297 Background: Adjuvant chemotherapy treatment for early stage @entity1149 @entity1 is not yet standard practice. The aim of the present trial is to compare the activity, safety, and quality of life effects of adjuvant @entity1205 plus @entity900 versus observation only. METHODS: @entity1 with completely resected stage I-II @entity1149 , no prior chemotherapy and/or radiotherapy, and a WHO performance status of <= 2, were randomized to @entity1205 plus @entity900 , 75 mg/m(2) each, both on day 1, every 21 days for 6 cycles (arm A) versus observation only (arm B). Time-to-event endpoints were calculated using the Kaplan-Meier method and compared between arms using the log-rank test. The incidence of grade 3 and 4 @entity137 was compared using Pearson's chi-squared test. The primary objective is disease-free survival; secondary objectives are overall survival, treatment-related @entity137 , and quality of life. Planned recruitment is 80 @entity1 . RESULTS: From December 2001 to December 2003, 30 @entity1 were randomized to each arm. There were 22 males and 8 females in each arm. Arm A: 17 @entity1 had stage I and 13 @entity1 @entity34 ; arm B: 18 @entity1 had stage I and 12 @entity34 . Mean age (range) arm A was 58.1 years (44 - 77) and arm B was 56.9 (46 - 72). An interim analysis of @entity137 in the treatment arm after inclusion of 40 @entity1 (20 arm A; 20 arm B) revealed that 64% (13 of 20) experienced @entity1210 grade 3 or 4; 43% (9 of 20) peripheral @entity2359 2 or 3; and 50% (10 of 20) experienced @entity1295 grade 2 or 3. Furthermore a significant decrease in @entity1 ' quality of life was noted during the 5(th) and 6(th) chemotherapy cycles. Based on this analysis, a protocol amendment reduced the total number of cycles to 4, with a further 2 cycles administered at investigators' discretion. Current relapse rates and time to progression will be reported at the meeting. CONCLUSIONS: The administration of 4 cycles of @entity1205 plus @entity900 is feasible in the adjuvant setting for @entity1 with stage I/II @entity1149 . No significant financial relationships to disclose.

title: Adjuvant @entity1205 plus XXXX in stage I/II @entity1149 ( @entity1149 ): Preliminary results of a randomized phase II pilot trial of the Central European Cooperative Oncology Group (CECOG).

entities_list: @entity1210 :: ('MESH:C536227', 'Disease') :: ['leucopenia']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel']

entities_list: @entity2359 :: ('MESH:D020258', 'Disease') :: ['neurotoxicity']

entities_list: @entity34 :: ('MESH:D016609', 'Disease') :: ['stage II disease']

answer: @entity900 :: (MESH:D002945,Chemical) :: ['cisplatin']


abstract: UNASSIGNED: 7297 Background: Adjuvant chemotherapy treatment for early stage @entity1149 @entity1 is not yet standard practice. The aim of the present trial is to compare the activity, safety, and quality of life effects of adjuvant @entity1205 plus @entity900 versus observation only. METHODS: @entity1 with completely resected stage I-II @entity1149 , no prior chemotherapy and/or radiotherapy, and a WHO performance status of <= 2, were randomized to @entity1205 plus @entity900 , 75 mg/m(2) each, both on day 1, every 21 days for 6 cycles (arm A) versus observation only (arm B). Time-to-event endpoints were calculated using the Kaplan-Meier method and compared between arms using the log-rank test. The incidence of grade 3 and 4 @entity137 was compared using Pearson's chi-squared test. The primary objective is disease-free survival; secondary objectives are overall survival, treatment-related @entity137 , and quality of life. Planned recruitment is 80 @entity1 . RESULTS: From December 2001 to December 2003, 30 @entity1 were randomized to each arm. There were 22 males and 8 females in each arm. Arm A: 17 @entity1 had stage I and 13 @entity1 @entity34 ; arm B: 18 @entity1 had stage I and 12 @entity34 . Mean age (range) arm A was 58.1 years (44 - 77) and arm B was 56.9 (46 - 72). An interim analysis of @entity137 in the treatment arm after inclusion of 40 @entity1 (20 arm A; 20 arm B) revealed that 64% (13 of 20) experienced @entity1210 grade 3 or 4; 43% (9 of 20) peripheral @entity2359 2 or 3; and 50% (10 of 20) experienced @entity1295 grade 2 or 3. Furthermore a significant decrease in @entity1 ' quality of life was noted during the 5(th) and 6(th) chemotherapy cycles. Based on this analysis, a protocol amendment reduced the total number of cycles to 4, with a further 2 cycles administered at investigators' discretion. Current relapse rates and time to progression will be reported at the meeting. CONCLUSIONS: The administration of 4 cycles of @entity1205 plus @entity900 is feasible in the adjuvant setting for @entity1 with stage I/II @entity1149 . No significant financial relationships to disclose.

title: Adjuvant @entity1205 plus @entity900 in stage I/II XXXX ( @entity1149 ): Preliminary results of a randomized phase II pilot trial of the Central European Cooperative Oncology Group (CECOG).

answer: @entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']


abstract: UNASSIGNED: 7297 Background: Adjuvant chemotherapy treatment for early stage @entity1149 @entity1 is not yet standard practice. The aim of the present trial is to compare the activity, safety, and quality of life effects of adjuvant @entity1205 plus @entity900 versus observation only. METHODS: @entity1 with completely resected stage I-II @entity1149 , no prior chemotherapy and/or radiotherapy, and a WHO performance status of <= 2, were randomized to @entity1205 plus @entity900 , 75 mg/m(2) each, both on day 1, every 21 days for 6 cycles (arm A) versus observation only (arm B). Time-to-event endpoints were calculated using the Kaplan-Meier method and compared between arms using the log-rank test. The incidence of grade 3 and 4 @entity137 was compared using Pearson's chi-squared test. The primary objective is disease-free survival; secondary objectives are overall survival, treatment-related @entity137 , and quality of life. Planned recruitment is 80 @entity1 . RESULTS: From December 2001 to December 2003, 30 @entity1 were randomized to each arm. There were 22 males and 8 females in each arm. Arm A: 17 @entity1 had stage I and 13 @entity1 @entity34 ; arm B: 18 @entity1 had stage I and 12 @entity34 . Mean age (range) arm A was 58.1 years (44 - 77) and arm B was 56.9 (46 - 72). An interim analysis of @entity137 in the treatment arm after inclusion of 40 @entity1 (20 arm A; 20 arm B) revealed that 64% (13 of 20) experienced @entity1210 grade 3 or 4; 43% (9 of 20) peripheral @entity2359 2 or 3; and 50% (10 of 20) experienced @entity1295 grade 2 or 3. Furthermore a significant decrease in @entity1 ' quality of life was noted during the 5(th) and 6(th) chemotherapy cycles. Based on this analysis, a protocol amendment reduced the total number of cycles to 4, with a further 2 cycles administered at investigators' discretion. Current relapse rates and time to progression will be reported at the meeting. CONCLUSIONS: The administration of 4 cycles of @entity1205 plus @entity900 is feasible in the adjuvant setting for @entity1 with stage I/II @entity1149 . No significant financial relationships to disclose.

title: Adjuvant @entity1205 plus @entity900 in stage I/II @entity1149 ( XXXX ): Preliminary results of a randomized phase II pilot trial of the Central European Cooperative Oncology Group (CECOG).

answer: @entity1149 :: (MESH:D002289,Disease) :: ['NSCLC']


abstract: UNASSIGNED: 7297 Background: Adjuvant chemotherapy treatment for early stage @entity1149 @entity1 is not yet standard practice. The aim of the present trial is to compare the activity, safety, and quality of life effects of adjuvant @entity1205 plus @entity900 versus observation only. METHODS: @entity1 with completely resected stage I-II @entity1149 , no prior chemotherapy and/or radiotherapy, and a WHO performance status of <= 2, were randomized to @entity1205 plus @entity900 , 75 mg/m(2) each, both on day 1, every 21 days for 6 cycles (arm A) versus observation only (arm B). Time-to-event endpoints were calculated using the Kaplan-Meier method and compared between arms using the log-rank test. The incidence of grade 3 and 4 @entity137 was compared using Pearson's chi-squared test. The primary objective is disease-free survival; secondary objectives are overall survival, treatment-related @entity137 , and quality of life. Planned recruitment is 80 @entity1 . RESULTS: From December 2001 to December 2003, 30 @entity1 were randomized to each arm. There were 22 males and 8 females in each arm. Arm A: 17 @entity1 had stage I and 13 @entity1 @entity34 ; arm B: 18 @entity1 had stage I and 12 @entity34 . Mean age (range) arm A was 58.1 years (44 - 77) and arm B was 56.9 (46 - 72). An interim analysis of @entity137 in the treatment arm after inclusion of 40 @entity1 (20 arm A; 20 arm B) revealed that 64% (13 of 20) experienced @entity1210 grade 3 or 4; 43% (9 of 20) peripheral @entity2359 2 or 3; and 50% (10 of 20) experienced @entity1295 grade 2 or 3. Furthermore a significant decrease in @entity1 ' quality of life was noted during the 5(th) and 6(th) chemotherapy cycles. Based on this analysis, a protocol amendment reduced the total number of cycles to 4, with a further 2 cycles administered at investigators' discretion. Current relapse rates and time to progression will be reported at the meeting. CONCLUSIONS: The administration of 4 cycles of @entity1205 plus @entity900 is feasible in the adjuvant setting for @entity1 with stage I/II @entity1149 . No significant financial relationships to disclose.

title: Adjuvant XXXX plus @entity900 in stage I/II @entity1149 ( @entity1149 ): Preliminary results of a randomized phase II pilot trial of the Central European Cooperative Oncology Group (CECOG).

answer: @entity1205 :: (MESH:C067311,Chemical) :: ['docetaxel']


abstract: Nephroid @entity4648 is an unusual lesion confined to the lamina propria of the lower urinary tract. It is defined by a characteristic histologic picture of tubular structures, formed by a single layer of cuboidal cells, surrounded by a thick basement membrane. Two main theories concerning the histogenesis of the condition have been proposed: embryonic origin, or @entity4648 . Five cases of @entity1358 were studied light-microscopically and by immunohistochemistry for the content of Tamm Horsfall's uromucoprotein. In addition, one case was examined by electron microscopy. The results were compared to current knowledge of the lesion obtained from a survey of the literature, with special reference to histogenesis. Morphologically, one case of @entity1358 was associated with @entity420 . It is concluded that @entity1358 arises as a metaplastic lesion, nearly always in previously traumatized urothelial mucosa. The natural history of the typical @entity1358 is benign, but a possible relationship to @entity420 , representing the malignant counterpart of the lesion, is discussed in relation to the histological findings, suggesting a rare but possible malignant potential of @entity1358 . The diverse nomenclature used for this histologic entity needs re-evaluation and should be changed to: @entity1358 .

title: Nephroid XXXX of the urinary tract. A survey of the literature, with the contribution of 5 new immunohistochemically studied cases, including one case examined by electron microscopy.

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['nephroid metaplasia']

entities_list: @entity4648 :: ('MESH:D008679', 'Disease') :: ['metaplasia']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['mesonephroid adenocarcinoma']

answer: @entity4648 :: (MESH:D008679,Disease) :: ['metaplasia']


abstract: UNASSIGNED: 8528 Background: Improved diagnosis and @entity5 has increased the overall survival rate. This study assesses @entity73 , functional limitations, health status and behaviors; and vocational and occupational histories of adult survivors of pediatric @entity242 . METHODS: Physical impairment assessment: Joint range of motion (ROM); manual muscle testing (MMT); hand grip strength (HGS). Functional limitations: Assessment of motor and process skills (AMPS); 6-minute walk (6MWT); and @entity1 activity performance (HAP) questionnaire. Health status and behaviors: Leisure satisfaction measure (LSM); SF-36; sickness impact profile (SIP). Vocational and occupational histories: The Goldberg Scale (GS). STATISTICS: Standardized measures compared @entity1 with norms. The results were evaluated by Wilcoxon signed rank two-sided p-values, unadjusted for multiple comparisons. RESULTS: 32 survivors were diagnosed at median age 15.4 years (male:female=17:15, @entity2828 in 24/32). ROM of 22 subjects tested was >40% reduced in 12/13 with lower extremity (LE) lesions. HGS equaled matched norms. 28 /32 performed the 6MWT. 3/4 non-ambulatory subjects were LE amputees. Velocity in 9 was <90% predicted. HAP maximum score/maximum adjusted scores were lower than matched norms (p=0.015 and p=0.043 respectively). Motor and process scores for performance of routine daily tasks were lower than normal matched controls (p<0.0001). SF36 physical competency subscale trended lower (p=0.065), mental competency scores trended higher (p=0.058) than normal, respectively. Overall LSM was higher than the control group (p<0.001). Preliminary GS evaluation suggests higher work satisfaction. CONCLUSION: Survivors of childhood @entity242 have residual impairment of strength and motion, more likely of the lower extremity. Performance(mobility and daily routines), was reduced. Leisure satisfaction and self-reported mental competency higher than matched normal subjects, despite significant physical limitations, may reflect an augmented sense of well-being. Vocational drive and occupational behaviors were above average compared to @entity1 with disabilities. No significant financial relationships to disclose.

title: Rehabilitation assessments of pediatric XXXX survivors.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients', 'people']

entities_list: @entity2828 :: ('MESH:D012512', 'Disease') :: ["Ewing's sarcoma"]

entities_list: @entity242 :: ('MESH:D012509', 'Disease') :: ['sarcoma', 'sarcomas']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['comprehensive treatment of childhood cancers']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['physical impairments']

answer: @entity242 :: (MESH:D012509,Disease) :: ['sarcoma']


abstract: BACKGROUND: R0 resection rates ( @entity5 removal with negative resection margins) in @entity788 are 70-80 per cent when a 0-mm margin is used, declining to 15-24 per cent with a 1-mm margin. This review evaluated the R0 resection rates according to different margin definitions and techniques. METHODS: Three databases (MEDLINE from 1946, PubMed from 1946 and Embase from 1949) were searched to mid-October 2014. The search terms included 'pancreatectomy OR pancreaticoduodenectomy' and 'margin'. A meta-analysis was performed with studies in three groups: group 1, axial slicing technique (minimum 1-mm margin); group 2, other slicing techniques (minimum 1-mm margin); and group 3, studies with minimum 0-mm margin. RESULTS: The R0 rates were 29 (95 per cent c.i. 26 to 32) per cent in group 1 (8 studies; 882 @entity1 ) and 49 (47 to 52) per cent in group 2 (6 studies; 1568 @entity1 ). The combined R0 rate (groups 1 and 2) was 41 (40 to 43) per cent. The R0 rate in group 3 (7 studies; 1926 @entity1 ) with a 0-mm margin was 72 (70 to 74) per cent The survival hazard ratios (R1 resection/R0 resection) revealed a reduction in the risk of death of at least 22 per cent in group 1, 12 per cent in group 2 and 23 per cent in group 3 with an R0 compared with an R1 resection. Local recurrence occurred more frequently with an R1 resection in most studies. CONCLUSION: Margin clearance definitions affect R0 resection rates in @entity788 surgery. This review collates individual studies providing an estimate of achievable R0 rates, creating a benchmark for future trials.

title: Meta-analysis of radical resection rates and margin assessment in XXXX .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['complete tumour']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic cancer']

answer: @entity788 :: (MESH:D010190,Disease) :: ['pancreatic cancer']


abstract: BACKGROUND: Nosocomial norovirus infections and their control measures disrupt @entity1 care, increase staff workload and raise healthcare costs. OBJECTIVE: To determine the impact on outbreaks of nosocomial @entity1800 , staff and @entity1 affected, and bed closures of a multidimensional quality improvement (QI) initiative focused on education; improved @entity1 surveillance; early automated recognition and notification of @entity281 of index @entity1 ; and proactive care and control measures. METHODS: In a pragmatic, retrospective, observational study, we compared numbers of suspected/confirmed norovirus outbreaks at Portsmouth Hospitals National Health Service Trust ( @entity120 ) with regional and national data, before and after a multidimensional QI initiative. We also compared mean daily bed closures due to norovirus-like symptoms. At @entity120 only we recorded @entity1 and staff numbers with norovirus-like symptoms, and days of disruption due to outbreaks. RESULTS: Annual outbreak numbers fell between 2009-2010 and 2010-2014 by 91% at @entity120 compared with 15% and 28% for Wessex and England, respectively. After April 2010, recorded outbreaks were 8 ( @entity120 ), 383 (Wessex) and 5063 (England). For the winter periods from 2010/2011 to 2013/2014, total bed closures due to norovirus were 38 ( @entity120 ; mean 0.5 per week), 3565 (Wessex hospitals; mean 48.8 per hospital per week) and 2730 (England; mean 37.4 per hospital per week). At @entity120 , @entity1 affected by norovirus-like symptoms fell by 92%, affected staff by 81% and days of disruption by 88%. CONCLUSIONS: A multiyear QI programme, including use of real-time electronic identification of @entity1 with norovirus-like symptoms, and an early robust response to suspected @entity281 , resulted in virtual elimination of outbreaks. The ability to identify index cases of @entity281 early facilitates prompt action to prevent ongoing transmission and appears to be a crucial intervention.

title: Reducing the number and impact of outbreaks of nosocomial XXXX : time-series analysis of a multidimensional quality improvement initiative.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity1800 :: ('MESH:D014777', 'Disease') :: ['viral gastroenteritis']

answer: @entity1800 :: (MESH:D014777,Disease) :: ['viral gastroenteritis']